Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
30 studies found for:    Open Studies | "Telangiectasis"
Show Display Options
Rank Status Study
1 Recruiting Institutional Registry of Haemorrhagic Hereditary Telangiectasia
Condition: Haemorrhagic Hereditary Telangiectasia
Intervention:
2 Recruiting Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias
Condition: Telangiectasias
Interventions: Drug: Brimonidine;   Other: IPL+air-cooling
3 Recruiting Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Condition: Hereditary Hemorrhagic Telangiectasia
Interventions: Drug: Topical timolol maleate;   Drug: placebo saline drops
4 Recruiting Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
Condition: Telangiectasia, Hereditary Hemorrhagic
Intervention: Drug: bevacuzimab spray
5 Recruiting Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
Condition: Telangiectasia, Hereditary Hemorrhagic
Interventions: Drug: Pazopanib;   Drug: Placebo
6 Recruiting Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia
Condition: Hereditary Haemorrhagic Telangiectasia (HHT)
Intervention: Other: questionnaire
7 Recruiting Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Condition: Hereditary Hemorrhagic Telangiectasia
Intervention:
8 Recruiting Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
Condition: Hemorrhagic Hereditary Telangiectasia (HHT)
Interventions: Drug: Timolol nasal spray;   Drug: Placebo nasal spray
9 Recruiting Iron Deficiency and Hereditary Haemorrhagic Telangiectasia
Condition: Hereditary Haemorrhagic Telangiectasia
Intervention: Drug: Ferrous sulphate 200mg oral tablet
10 Recruiting Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Condition: Telangiectasia, Hereditary Hemorrhagic
Intervention:
11 Recruiting Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone
Condition: Ataxia-Telangiectasia
Interventions: Drug: Metformin;   Drug: Pioglitazone
12 Recruiting QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Conditions: Breast Cancer;   Radiation-Induced Telangiectasias
Intervention: Behavioral: questionnaires
13 Recruiting Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Condition: Telangiectasia, Hereditary Hemorrhagic
Intervention:
14 Recruiting Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia
Condition: Ataxia-Telangiectasia (A-T)
Interventions: Other: with gene correction;   Other: without gene correction
15 Recruiting MRA With Feraheme in HHT
Condition: Hereditary Hemorrhagic Telangiectasia
Intervention:
16 Not yet recruiting Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Conditions: Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Interventions: Drug: Mupirocin;   Other: Placebo
17 Recruiting Graded TTCE for Post-Embolization PAVM Monitoring
Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Other: Transthoracic Contrast Echocardiogram
18 Recruiting Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Conditions: Hereditary Hemorrhagic Telangiectasia (HHT);   Epistaxis
Interventions: Drug: Floseal;   Other: Packing
19 Recruiting Immunmodulation in Patients With HHT
Condition: Hereditary Haemorrhagic Telangiectasia (HHT)
Intervention: Other: blood sample
20 Not yet recruiting EDS in Ataxia Telangiectasia Patients
Conditions: Nervous System Disease;   Genetic Disease;   Rare Disease
Interventions: Drug: EDS-EP dose range of ~5-10 mg DSP/infusion;   Drug: EDS-EP dose range of ~14-22 mg DSP/infusion;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.